No improvement in the overall survival of 194 patients with chondrosarcoma in Finland in 1971-1990.

Acta Orthop Scand

Skeletal Research Program, Department of Medical Biochemistry and Molecular Biology, University of Turku, FI-20520 Turku, Finland.

Published: June 2003

We describe the clinicopathologic profile and survival of 306 patients with chondrosarcoma reported to the Finnish Cancer Registry in 1971-1990. 218 cases were available for reevaluation. Owing to their various clinicopathologic characteristics, we excluded the histologic variants of chondrosarcoma. Therefore, the final study population included 194 patients. The minimum follow-up was 9 years. The study population included 69 grade 1 tumors, 114 grade 2 tumors, and 11 grade 3 tumors. The commonest tumor sites were the chest, pelvis and femur. A local recurrence developed in 25% of the patients and metastatic lesions in 18%. The patients were treated in 31 hospitals (in 22 hospitals during the 1970s and in 26 in the 1980s), and the number of patients biopsied before the referral remained about the same from the 1970s (15%) to the 1980s (18%). The 5-and 10-year disease-specific survival rates were 70% and 57%, respectively. Multivariate analysis showed that the most important independent predictors of shortened survival were high histologic grade, age 50 years or older, and a diagnosis in the 1980s, as compared to the 1970s. Most findings accorded with reports from specialist treatment centers, but to our surprise, the survival rate declined among patients diagnosed in the 1980s versus the 1970s. The failure to improve patient survival is probably due to treatment of the patients in 31 hospitals rather than in a few centers dealing with treatment of cancer.

Download full-text PDF

Source
http://dx.doi.org/10.1080/00016470310014292DOI Listing

Publication Analysis

Top Keywords

grade tumors
12
patients
8
194 patients
8
patients chondrosarcoma
8
study population
8
population included
8
survival
5
improvement survival
4
survival 194
4
chondrosarcoma finland
4

Similar Publications

Decoding Epilepsy: Prickle2 and Multifaceted Molecular Pathway Connections.

Curr Pharm Des

January 2025

Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, Hubei, China.

Background: The Prickle2 (Pk2) gene shows promising potential in uncovering the underlying causes of epilepsy, a neurological disorder that is currently not well understood. This paper utilizes the online tool PubMed to gather and condense information on the involvement of PCP channels and the associated roles of PCP pathway molecules in the onset of epilepsy. These findings are significant for advancing epilepsy treatment.

View Article and Find Full Text PDF

A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+/HER2- breast cancer-FINEST study.

Cancer Commun (Lond)

January 2025

Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Centre, Shanghai, P. R. China.

Background: Hormone receptor-positive (HR+)/humaal growth factor receptor 2-negative (HER2-) breast cancer, the most common breast cancer type, has variable prognosis and high recurrence risk. Neoadjuvant therapy is recommended for median-high risk HR+/HER2- patients. This phase II, single-arm, prospective study aimed to explore appropriate neoadjuvant treatment strategies for HR+/HER2- breast cancer patients.

View Article and Find Full Text PDF

Background: This study aimed to evaluate the incidence, contributing factors, and clinical outcomes of acquired cystic kidney disease (ACKD) in children undergoing kidney replacement therapy (KRT).

Methods: We conducted a cross-sectional, territory-wide study at the designated pediatric nephrology center in Hong Kong. ACKD was defined as the presence of ≥ 3 cysts in the native kidneys, excluding congenital or hereditary cystic diseases.

View Article and Find Full Text PDF

Aim: This study aimed to investigate the effect of the COVID-19 pandemic on the clinical and pathological stages of patients diagnosed with breast cancer.

Method: In this retrospective study, a total of 298 male and female patients over the age of 18 who were diagnosed with breast cancer and who were continuing surgical and oncologic treatment were included.

Results: Of the 298 patients diagnosed with breast cancer, 186 (62.

View Article and Find Full Text PDF

Breast cancer (BC) is a substantial reason for cancer-related mortality among women across the globe. Anastrozole (ANS) is an effective orally administered hormonal therapy for estrogen+ (ER+) BC treatment. However, several side effects and pharmacokinetic limitations restricted its uses in BC treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!